Proteasome activator enhances survival of Huntington's disease neuronal model cells

PLoS ONE

Volumn 2, Issue 2, 2007, Pages

  Seo, Hyemyung ^a,b   Sonntag, Kai Christian ^a   Kim, Woori ^b   Cattaneo, Elena ^c   Isacson, Ole ^a  

^a MCLEAN HOSPITAL   (United States)

^b Hanyang University   (South Korea)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; EXCITOTOXIN; HUNTINGTIN; LENTIVIRUS VECTOR; NUCLEAR PROTEIN; PROTEASOME; PROTEASOME ACTIVATOR SUBUNIT 28 GAMMA; PROTEASOME ACTIVATOR SUBUNIT 5 ALPHA; QUINOLINIC ACID; UBIQUITIN; UNCLASSIFIED DRUG; 3 NITROPROPIONIC ACID; 3-NITROPROPIONIC ACID; BENZYLOXYCARBONYLLEUCYL LEUCYL LEUCINE ALDEHYDE; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; HD PROTEIN, HUMAN; HYBRID PROTEIN; LEUPEPTIN; MUSCLE PROTEIN; NERVE PROTEIN; NITRO DERIVATIVE; PEPTIDE FRAGMENT; PROPIONIC ACID DERIVATIVE; PROTEASOME ACTIVATOR PA700 SUBUNIT P58, HUMAN; PSMD4 PROTEIN, HUMAN; PSME1 PROTEIN, HUMAN;

ARTICLE; CELL FUNCTION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; GENE MUTATION; GENE OVEREXPRESSION; GENE TRANSFER; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; IMMUNOSTIMULATION; NERVE CELL; NEUROPROTECTION; PROTEIN DEGRADATION; PROTEIN FUNCTION; SKIN FIBROBLAST; STRIATE CORTEX; CELL CULTURE; CORPUS STRIATUM; CYTOLOGY; DRUG EFFECT; FIBROBLAST; GENETIC TRANSDUCTION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; UPREGULATION;

CELL SURVIVAL; CELLS, CULTURED; CORPUS STRIATUM; FIBROBLASTS; HUMANS; HUNTINGTON DISEASE; LEUPEPTINS; MUSCLE PROTEINS; NERVE TISSUE PROTEINS; NEURONS; NITRO COMPOUNDS; NUCLEAR PROTEINS; PEPTIDE FRAGMENTS; PROPIONIC ACIDS; PROTEASOME ENDOPEPTIDASE COMPLEX; QUINOLINIC ACID; RECOMBINANT FUSION PROTEINS; TRANSDUCTION, GENETIC; UBIQUITIN; UP-REGULATION;

EID: 34948845308     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0000238     Document Type: Article

References (50)

1. Paulson HL, Fischbeck KH (1996) Trinucleotide repeats in neurogenetic disorders. Annu Rev Neurosci 19: 79-107.
2. Myers RH (2004) Huntington's disease genetics. NeuroRx 1: 255-262.
3. Trottier Y, Devys D, Imbert G, Saudou F, An I, et al. (1995) Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nat Genet 10: 104-110.
4. Bowman AB, Yoo SY, Dantuma NP, Zoghbi HY (2005) Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation. Hum Mol Genet 14: 679-691.
5. Petrucelli L, Dawson TM (2004) Mechanism of neurodegenerative disease: role of the ubiquitin proteasome system. Ann Med 36: 315-320.
6. de Pril R, Fischer DF, Maat-Schieman ML, Hobo B, de Vos RA, et al. (2004) Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseases. Hum Mol Genet 13: 1803-1813.
7. Coux O, Tanaka K, Goldberg AL (1996) Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 65: 801-847.
8. Layfield R, Lowe J, Bedford L (2005) The ubiquitin-proteasome system and neurodegenerative disorders. Essays Biochem 41: 157-171.
9. Seo H, Sonntag KC, Isacson O (2004) Generalized brain and skin proteasome inhibition in Huntington's disease. Ann Neurol 56: 319-328.
10. Groll M, Huber R (2005) Purification, crystallization, and X-ray analysis of the yeast 20S proteasome. Methods Enzymol 398: 329-336.
11. Groll M, Bajorek M, Kohler A, Moroder L, Rubin DM, et al. (2000) A gated channel into the proteasome core particle. Nat Struct Biol 7: 1062-1067.
12. Kisselev AF, Callard A, Goldberg AL (2006) Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J Biol Chem 281: 8582-8590.
13. Kisselev AF, Garcia-Calvo M, Overkleeft HS, Peterson E, Pennington MW, et al. (2003) The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites. J Biol Chem 278: 35869-35877.
14. Rechsteiner M, Realini C, Ustrell V (2000) The proteasome activator 11 S REG (PA28) and class I antigen presentation. Biochem J 345 Pt 1: 1-15.
15. DeMartino GN, Slaughter CA (1999) The proteasome, a novel protease regulated by multiple mechanisms. J Biol Chem 274: 22123-22126.
16. Sipione S, Rigamonti D, Valenza M, Zuccato C, Conti L, et al. (2002) Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. Hum Mol Genet 11: 1953-1965.
17. Deveraux Q, van Nocker S, Mahaffey D, Vierstra R, Rechsteiner M (1995) Inhibition of ubiquitin-mediated proteolysis by the Arabidopsis 26 S protease subunit S5a. J Biol Chem 270: 29660-29663.
18. DeMartino GN, Moomaw CR, Zagnitko OP, Proske RJ, Chu-Ping M, et al. (1994) PA700, an ATP-dependent activator of the 20 S proteasome, is an ATPase containing multiple members of a nucleotide-binding protein family. J Biol Chem 269: 20878-20884.
19. Cory AH, Owen TC, Barltrop JA, Cory JG (1991) Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 3: 207-212.
20. Yamamoto A, Lucas JJ, Hen R (2000) Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101: 57-66.
21. Martin-Aparicio E, Yamamoto A, Hernandez F, Hen R, Avila J, et al. (2001) Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease. J Neurosci 21: 8772-8781.
22. Demasi M, Davies KJ (2003) Proteasome inhibitors induce intracellular protein aggregation and cell death by an oxygen-dependent mechanism. FEBS Lett 542: 89-94.
23. Chai Y, Koppenhafer SL, Shoesmith SJ, Perez MK, Paulson HL (1999) Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro. Hum Mol Genet 8: 673-682.
24. Bae BI, Hara MR, Cascio MB, Wellington CL, Hayden MR, et al. (2006) Mutant huntingtin: nuclear translocation and cytotoxicity mediated by GAPDH. Proc Natl Acad Sci U S A 103: 3405-3409.
25. Kaytor MD, Wilkinson KD, Warren ST (2004) Modulating huntingtin half-life alters polyglutamine-dependent aggregate formation and cell toxicity. J Neurochem 89: 962-973.
26. Xia H, Mao Q, Eliason SL, Harper SQ, Martins IH, et al. (2004) RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 10: 816-820.
27. Yamamoto A, Cremona ML, Rothman JE (2006) Autophagy-mediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway. J Cell Biol 172: 719-731.
28. Gidalevitz T, Ben-Zvi A, Ho KH, Brignull HR, Morimoto RI (2006) Progressive disruption of cellular protein folding in models of polyglutamine diseases. Science 311: 1471-1474.
29. Diaz-Hernandez M, Valera AG, Moran MA, Gomez-Ramos P, Alvarez-Castelao B, et al. (2006) Inhibition of 26S proteasome activity by huntingtin filaments but not inclusion bodies isolated from mouse and human brain. J Neurochem..
30. Lee HG, Petersen RB, Zhu X, Honda K, Aliev G, et al. (2003) Will preventing protein aggregates live up to its promise as prophylaxis against neurodegenerative diseases? Brain Pathol 13: 630-638.
31. Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, et al. (1997) Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol 41: 646-653.
32. Ruan Q, Lesort M, MacDonald ME, Johnson GV (2004) Striatal cells from mutant huntingtin knock-in mice are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a non-apoptotic pathway. Hum Mol Genet 13: 669-681.
33. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, et al. (1986) Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321: 168-171.
34. Beal MF, Kowall NW, Swartz KJ, Ferrante RJ, Martin JB (1988) Systemic approaches to modifying quinolinic acid striatal lesions in rats. J Neurosci 8: 3901-3908.
35. Roberts RC, DiFiglia M (1989) Short- and long-term survival of large neurons in the excitotoxic lesioned rat caudate nucleus: a light and electron microscopic study. Synapse 3: 363-371.
36. Barton LF, Runnels HA, Schell TD, Cho Y, Gibbons R, et al. (2004) Immune defects in 28-kDa proteasome activator gamma-deficient mice. J Immunol 172: 3948-3954.
37. Yee WM, Frim DM, Isacson O (1993) Relationships between stress protein induction and NMDA-mediated neuronal death in the entorhinal cortex. Exp Brain Res 94: 193-202.
38. Metere A, Mallozzi C, Minetti M, Domenici MR, Pezzola A, et al. (2006) Quinolinic acid modulates the activity of src family kinases in rat striatum: in vivo and in vitro studies. J Neurochem 97: 1327-1336.
39. Simpson JR, Isacson O (1993) Mitochondrial impairment reduces the threshold for in vivo NMDA-mediated neuronal death in the striatum. Exp Neurol 121: 57-64.
40. Brouillet E, Jacquard C, Bizat N, Blum D (2005) 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J Neurochem 95: 1521-1540.
41. Jacquard C, Trioulier Y, Cosker F, Escartin C, Bizat N, et al. (2006) Brain mitochondrial defects amplify intracellular [Ca2+] rise and neurodegeneration but not Ca2+ entry during NMDA receptor activation. Faseb J 20: 1021-1023.
42. Kominami K, Okura N, Kawamura M, DeMartino GN, Slaughter CA, et al. (1997) Yeast counterparts of subunits S5a and p58 (S3) of the human 26S proteasome are encoded by two multicopy suppressors of nin1-1. Mol Biol Cell 8: 171-187.
43. Li J, Rechsteiner M (2001) Molecular dissection of the 11S REG (PA28) proteasome activators. Biochimie 83: 373-383.
44. Glickman MH, Ciechanover A (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82: 373-428.
45. Bett JS, Goellner GM, Woodman B, Pratt G, Rechsteiner M, et al. (2006) Proteasome impairment does not contribute to pathogenesis in R6/2 Huntington's disease mice: exclusion of proteasome activator REGgamma as a therapeutic target. Hum Mol Genet 15: 33-44.
46. Seo H, Sonntag KC, Lee CH, Kim HT, Isacson O (2005) Generalized ubiquitin proteasome inhibitiion in Huntington's disease patients' brains is modeled in some but not all HD transgenic mice. Annual conference of Society for Neuroscience.
47. Hansson O, Petersen A, Leist M, Nicotera P, Castilho RF, et al. (1999) Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proc Natl Acad Sci U S A 96: 8727-8732.
48. Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, et al. (1998) Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 72: 9873-9880.
49. Rigamonti D, Bauer JH, De-Fraja C, Conti L, Sipione S, et al. (2000) Wild-type huntingtin protects from apoptosis upstream of caspase-3. J Neurosci 20: 3705-3713.
50. Craiu A, Gaczynska M, Akopian T, Gramm CF, Fenteany G, et al. (1997) Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J Biol Chem 272: 13437-13445.